Sixth Wave Innovations (SIXW.C) research team finished the first molecular imprint of the SARS-CoV-2 virus using its AMIPs process and technology today, according to a press release.

The AMIPS Imprint tech is a polymer imprint prototype which gives a detailed topographical impression of the virus and and chemical binding sites required for recapture. The imprint will go through some validation tests at Uof A to determine the accuracy of the process.

“This is an important accomplishment in the AMIPs development cycle. With the completion of the initial imprint, we’ve demonstrated the process of making this polymer. More importantly, we now have an AMIPs prototype customized for SARS-CoV-2, which we can run through a battery of tests, optimizing its design with each successive imprint version. At the end of this process, we aim to have a Definitive Imprint with an extremely high affinity, or attraction, to the Virus, with clinically relevant detection levels and reliability,” said Dr. Jonathan Gluckman, president and CEO of Sixth Wave.

Sixth Wave is a nanotechnology company with patents dealing with extraction and detection of substances at a molecular level using their specialized Molecularly Imprinted Polymers, or MIPs. In addition to AMIPs, for viruses, they’re in the process of producing a commercial cannabinoid purification system called Affinity, as well as IXOS, which is an extraction polymer system for the gold mining industry.

The company intends to use the feedback from the validation process to generate future versions until they find a master imprinting capable of identifying the virus with advanced accuracy, and that is what they intend to use in their AMIPs virus detection products. These include handheld devices, wearables and airborne detection tools.

Source: stockwatch.com

Sixth Wave has enjoyed a 10.9% pop on the day, and is now presently trading at $0.355.

—Joseph Morton

Full disclosure: Sixth Wave Innovations is an equity.guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Biotech
AMIPs
bacteria
Best Canadian Biotech
biotechnology
corona virus
Coronavirus
COVID-19
Dr. Gluckman
Dr. Jonathan Gluckman
hot shot Tech team
Molecularly Imprinted Polymers
SARS-CoV-2
Sixth Wave Innovations
SIXW.C
viruses
viruses and bacteria
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x